Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 24;2014(6):CD007210.
doi: 10.1002/14651858.CD007210.pub3.

Maintenance treatments for opiate -dependent adolescents

Silvia Minozzi  1 , Laura Amato, Cristina Bellisario, Marina Davoli
Affiliations

Maintenance treatments for opiate -dependent adolescents

Silvia Minozzi et al. Cochrane Database Syst Rev. .

Abstract

Background: The scientific literature examining effective treatments for opioid-dependent adults clearly indicates that pharmacotherapy is a necessary and acceptable component. Nevertheless, no reviews have been published that systematically assess the effectiveness of pharmacological maintenance treatment in adolescents.

Objectives: To assess the effectiveness of any maintenance treatment alone or in combination with psychosocial intervention compared to no intervention, other pharmacological intervention or psychosocial interventions for retaining adolescents in treatment, reducing the use of substances and improving health and social status.

Search methods: We searched the Cochrane Drugs and Alcohol Group's Trials Register (January 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 1), PubMed (January 1966 to January 2014), EMBASE (January 1980 to January 2014), CINAHL (January 1982 to January 2014), Web of Science (1991 to January 2014) and reference lists of articles.

Selection criteria: Randomised and controlled clinical trials of any maintenance pharmacological interventions either alone or associated with psychosocial intervention compared with no intervention, placebo, other pharmacological intervention, pharmacological detoxification or psychosocial intervention in adolescents (13 to 18 years).

Data collection and analysis: We used the standard methodological procedures expected by The Cochrane Collaboration.

Main results: We included two trials involving 189 participants. One study, with 35 participants, compared methadone with levo-alpha-acetylmethadol (LAAM) for maintenance treatment lasting 16 weeks, after which patients were detoxified. The other study, with 154 participants, compared maintenance treatment with buprenorphine-naloxone and detoxification with buprenorphine. We did not perform meta-analysis because the two studies assessed different comparisons.In the study comparing methadone and LAAM, the authors declared that there was no difference in the use of a substance of abuse or social functioning (data not shown). The quality of the evidence was very low. No side effects, such as nausea, vomiting, constipation, weakness or fatigue, were reported by study participants.In the comparison between buprenorphine maintenance and buprenorphine detoxification, maintenance treatment appeared to be more efficacious in retaining patients in treatment (drop-out risk ratio (RR) 0.37; 95% confidence interval (CI) 0.26 to 0.54), but not in reducing the number of patients with a positive urine test at the end of the study (RR 0.97; 95% CI 0.78 to 1.22). Self reported opioid use at one-year follow-up was significantly lower in the maintenance group, even though both groups reported a high level of opioid use (RR 0.73; 95% CI 0.57 to 0.95). More patients in the maintenance group were enrolled in other addiction treatment programmes at 12-month follow-up (RR 1.33; 95% CI 0.94 to 1.88). The quality of the evidence was low. No serious side effects attributable to buprenorphine-naloxone were reported by study participants and no patients were removed from the study due to side effects. The most common side effect was headache, which was reported by 16% to 21% of patients in both groups

Authors' conclusions: It is difficult to draft conclusions on the basis of only two trials. One of the possible reasons for the lack of evidence could be the difficulty of conducting trials with young people for practical and ethical reasons.There is an urgent need for further randomised controlled trials comparing maintenance treatment with detoxification treatment or psychosocial treatment alone before carrying out studies that compare different pharmacological maintenance treatments. These studies should have long follow-up and measure relapse rates after the end of treatment and social functioning (integration at school or at work, family relationships).

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Flow chart of studies in the review published in 2009.
2
2
Study flow diagram for 2014 update.
3
3
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
4
4
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 1 Drop‐outs.
1.2
1.2. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 2 Patients with positive urine test at the end of treatment.
1.3
1.3. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 3 Self reported heroin use at 12‐month follow‐up.
1.4
1.4. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 4 Enrolment in addiction treatment at 12‐month follow‐up.
1.5
1.5. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 5 Self reported alcohol use.
1.6
1.6. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 6 Self reported marijuana use.
1.7
1.7. Analysis
Comparison 1 Buprenorphine‐naloxone maintenance versus buprenorphine detoxification, Outcome 7 Self reported cocaine use.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Lehmann 1973 {published data only}
    1. Lehmann WX. The use of 1‐alpha‐acetyl‐methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. NIDA Research Monograph 1973;8:82‐3. - PubMed
Woody 2008 {published data only}
    1. Woody GE, Poole SA, Subramanian G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short term buprenorphine‐naloxone for treatment of opioid addicted youth: a randomized trial. JAMA 2008;300(17):2003‐11. [Erratum inJAMA. 2009 Feb 25;301(8):830.JAMA. 2013 Apr 10;309(14):1461] - PMC - PubMed

References to studies excluded from this review

Baer 2007 {published data only}
    1. Baer JS, Garret SB, Beadnell B, Wells EA, Peterson PL. Brief motivational intervention with homeless adolescents: evaluating effects on substance use and service utilization. Psychology of Addictive Behaviors 2007;21(4):582‐6. - PubMed
Chakrabarti 2010 {published data only}
    1. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine‐naloxone dosing in a 12‐week treatment trial for opioid‐dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug and Alcohol Dependence 2010;107(2‐3):253‐6. - PMC - PubMed
Ebner 2007 {published data only}
    1. Ebner R, Zierer C, Schreiber W. After detoxification is before detoxification? Long term outcome of drug dependent adolescent [Nach dem Entzug = vor dem Entzug? Langzeitvrlauf bei drogenabhangigen Jugendlichen]. Psychiatrische Praxis 2007;34(Suppl 1):s42‐3.
Fiellin 2008 {published data only}
    1. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA 2008;300(17):2057‐9. - PubMed
Forcehimes 2008 {published data only}
    1. Forcehimes AA, Bogenschutz MP, Tonigan JS, Woody GE. Impact of therapeutic alliance on treatment outcome in opioid dependent adolescent and young adult treated with buprenorphine. Proceedings of the 70th Annual Scientific Meeting of the College on Problems of Drug Dependence; Puerto Rico. 2008.
Godley 2004 {published data only}
    1. Godley SH, Dennis ML, Godely MD, Funk RR. Thirty‐months relapse trajectory cluster groups among adolescents discharged from out‐patients treatment. Addiction 2004;99(Suppl 2):129‐39. - PubMed
Hill 2013 {published data only}
    1. Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, et al. Association of cannabis use with opioid outcomes among opioid‐dependent youth. Drug and Alcohol Dependence 2013;132(1‐2):342‐5. - PMC - PubMed
Hulse 2010 {published data only}
    1. Hulse GK, Ngo HTT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biological Psychiatry 2010;68(3):296‐302. - PubMed
Kemp 2007 {published data only}
    1. Kemp R, Harris A, Vurel E, Siharthan T. Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatry 2007;15(6):490‐3. - PubMed
Lloyd 1974 {published data only}
    1. Lloyd RA, Katon RN, DuPont RL. Evolution of a treatment approach for young heroin addicts. Comparison of three treatment modalities. International Journal of Addiction 1974;9(2):229‐39. - PubMed
Marsch 2005 {published data only}
    1. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid‐dependent adolescents. Archives of General Psychiatry 2005;62:1157‐64. - PubMed
Marsch 2009 {published data only}
    1. March L, Moore SK, Solhkhah R, Badger GJ. Predictors of outcome in buprenorphine treatment for opioid‐dependent youth. Proceedings of the 71st Annual Scientific Meeting of the College on Problems of Drug Dependence; 2009 June 20‐25; Reno/Sparks, Nevada, USA. 2009.
    1. Marsch LA, Moore S, Solhkhah R. A randomized, controlled trial of buprenorphine dosing regimens for opioid dependent youth. Proceedings of the 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence; 2011 June 18‐23, Hollywood, Florida . 2011.
Moore 2014 {published data only}
    1. Moore SK, Guarino H, Marsch LA. "This is not who I want to be:" experiences of opioid‐dependent youth before, and during, combined buprenorphine and behavioral treatment. Substance Use and Misuse 2014;49(3):303‐14. - PMC - PubMed
Polsky 2010 {published data only}
    1. Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost‐effectiveness of extended buprenorphine‐naloxone treatment for opioid‐dependent youth: data from a randomized trial. Addiction 2010;105(9):1616‐24. - PMC - PubMed
Reimer 2011 {published data only}
    1. Reimer J, Verthein U, Karow A, Schafer I, Naber D, Haasen C. Physical and mental health in severe opioid‐dependent patients within a randomized controlled maintenance treatment trial. Addiction 2011;106(9):1647‐55. - PubMed
Subramaniam 2011 {published data only}
    1. Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid‐dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(11):1120‐8. - PMC - PubMed
Warden 2012 {published data only}
    1. Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Adaptive Behavior 2012;37(9):1046‐53. - PMC - PubMed
Weiss 2013 {published data only}
    1. Weiss L, Petry NM. Older methadone patients achieve greater durations of cocaine abstinence with contingency management than younger patients. American Journal on Addictions 2013;22(2):119‐26. - PMC - PubMed
Wilcox 2013 {published data only}
    1. Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G. Concordance between self‐report and urine drug screen data in adolescent opioid dependent clinical trial participants. Addictive Behaviors 2013;38(10):2568‐74. - PMC - PubMed

Additional references

AIHW 2011
    1. Australian Institute of Health and Welfare. Drugs in Australia 2010: tobacco, alcohol and other drugs. Drug statistics series no. 27. Cat. no. PHE 154. Canberra: AIHW. Drug Statistics Series No.18. Cat. no. PHE 80. Canberra: AIHW . Available at: http://www.aihw.gov.au/ 2011.
Altobelli 2005
    1. Altobelli E, Rapacchietta L, Tiberti S, Petrocelli R, Cicioni L, Orio F, et al. Association between drug, alcohol and tobacco use in adolescents and social‐familiar factors [Associazione tra l'uso di sostanze stupefacenti, alcol e tabacco negli adolescenti e contesto socio‐familiare]. Annali d'Igiene 2005;17:57‐65. - PubMed
Amato 2011
    1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD004147] - DOI - PubMed
Clark 2002
    1. Clark N, Lintzeris N, Gijsbers A, Whelan G, Ritter A, Dunlop A. LAAM maintenance versus methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002210] - DOI - PubMed
EMCDDA 2012
    1. European Monitoring Centre for Drug & Drug Addiction (EMCDDA). Annual Report: The state of the drugs problem. European Union and Norway. Office for Publications of the European Communities, Luxembourg 2012.
ESPAD 2012
    1. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al. The 2011 ESPAD report: substance use among students in 36 European countries, Swedish Council for Information on Alcohol and Other Drugs, Stockholm, Sweden. Available at: http://www.espad.org 2012.
Faggiano 2003
    1. Faggiano F, Vigna‐Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002208] - DOI - PubMed
Ferri 2011
    1. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin‐dependent individuals. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003410] - DOI - PMC - PubMed
Galanter 2007
    1. Galanter M, Glickman L, Singer D. An overview of outpatient treatment of adolescent substance abuse. Substance Abuse 2007;28(2):51‐8. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Available from www.cochrane‐handbook.org.
Hopfer 2002
    1. Hopfer CJ, Khurl E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. Journal of Substance Abuse Treatment 2002;23(3):231‐7. - PubMed
Hunt 1990
    1. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology 1990;1:87‐102. - PubMed
Kaminer 1995
    1. Kaminer Y. Pharmacotherapy for adolescents with psychoactive substance use disorders. NIDA Research Monograph 1995;156:291‐324. - PubMed
Kellogg 2006
    1. Kellogg S, Melia D, Khuri E, Lin A, Ho A, Kreek MJ. Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. Journal of Addictive Diseases 2006;25:15‐25. - PubMed
Levy 2007
    1. Levy S, Vaughan BL, Angulo M, Knight JR. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children’s hospital‐based outpatient treatment program. Journal of Adolescent Health 2007;40:477‐82. - PubMed
Lobmaier 2008
    1. Lobmaier PP, Kornør H, Kunøe N, Bjørndal A. Sustained‐release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004330] - DOI - PubMed
Mattick 2009
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002209] - DOI - PMC - PubMed
Mattick 2014
    1. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD002207] - DOI
Mayet 2005
    1. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004330] - DOI - PubMed
Minozzi 2011
    1. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD001333] - DOI - PubMed
Monitoring the Future 2013
    1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future. National survey results on drug use 1975–2012: 2012 overview. Key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan. Available at http://monitoringthefuture.org 2013.
SAMHSA 2013
    1. Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H‐46, HHS Publication No. (SMA) 13‐4795. Rockville, MD: Substance Abuse and Mental Health Services Administration 2013.
Smith 2012
    1. Smith B, Fagan J, Kernan k. Outcomes of heroin dependent adolescents presenting for opiate substitution treatment. Journal of Substance Abuse Treatment 2012;42:35‐44. - PubMed

Publication types

MeSH terms

LinkOut - more resources